446 patents currently held
21 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
176 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
177
Ending by 2030
Nov 2026
Next term end
215
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2029 · High confidence
Also notable
Ends May 2027 · High confidence
Also notable
Ends Aug 2027 · High confidence
Modulators of Atp-Binding Cassette Transporters
US 8,829,204
Cited by 141 later US patents, top 5% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Modulators of Atp-Binding Cassette Transporters
US 7,659,268
Cited by 166 later US patents, top 5% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
Modulators of Atp-Binding Cassette Transporters
US 8,623,905
Cited by 123 later US patents, top 5% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 5 fees due Nov 19 to 28, 2026 · next Nov 19
- 8 fees due Dec 2 to 30, 2026 · next Dec 2
- 2 fees due Jan 14 to 25, 2027 · next Jan 14
- 6 fees due Feb 4 to 27, 2027 · next Feb 4
- 4 fees due Mar 10 to 22, 2027 · next Mar 10
- 6 fees due Apr 3 to 30, 2027 · next Apr 3
- 10 fees due May 7 to 28, 2027 · next May 7
- 2 fees due Jun 5 to 10, 2027 · next Jun 5
- 5 fees due Jul 9 to 30, 2027 · next Jul 9
- 3 fees due Aug 2 to 25, 2027 · next Aug 2
- 5 fees due Sep 5 to 29, 2027 · next Sep 5
- 6 fees due Oct 2 to 26, 2027 · next Oct 2
- 4 fees due Nov 10 to 14, 2027 · next Nov 10
Recent changes
- 2 of the patents on this record were granted since Aug 18, 2026
- 18 terms have ended since Aug 18, 2026
What they patent
The 5 largest of its 215 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Pyrrolopyrazine-Spirocyclic Piperidine Amides as Modulators of Ion Channels | 18 in force | to Oct 2037 |
| Modulators of Atp-Binding Cassette Transporters | 16 in force | to Nov 2027 |
| Compounds Useful as Inhibitors of Atr Kinase | 8 in force | to May 2034 |
| DNA-Pk Inhibitors | 8 in force | to Apr 2033 |
| Solid Forms of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-Methylpyridin-2-YL)BENZOIC Acid | 8 in force | to Sep 2030 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,767,672 | Aminopyrimidines Useful as Kinase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 7,973,169 | Modulators of Atp-Binding Cassette Transporters In force · High confidence | In force | High confidence | |
| US 8,586,589 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels In force · High confidence | In force | High confidence | |
| US 7,691,902 | Modulators of Atp-Binding Cassette Transporters In force · High confidence | In force | High confidence | |
| US 8,410,274 | Solid Forms of N-[2,4-BIS(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide In force · Low confidence | In force | Low confidence | |
| US 8,754,224 | Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide In force · Low confidence | In force | Low confidence | |
| US 8,846,753 | Modulators of Atp-Binding Cassette Transporters In force · High confidence | In force | High confidence | |
| US 9,139,530 | Solid Forms of N-[2,4-BIS(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide In force · Medium confidence | In force | Medium confidence | |
| US 9,670,163 | Solid Forms of N-[2,4-BIS(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide In force · Low confidence | In force | Low confidence | |
| US 10,537,565 | Solid Forms of N-[2,4-BIS(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 446: 21 patents in force now held by others · 441 patents ended · 138 applications pending · 385 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.